308 results about "SCLC - Small cell lung cancer" patented technology

The invention discloses aptamer for typing different subtypes of non-small cell lung cancer and a method for screening the same. The aptamer provided by the invention is any DNA segment of nucleotide expressed by sequence 1 to sequence 9 in a sequence table. The aptamer is applied for typing different subtypes of non-small cell lung cancer. The aptamer of the invention can differentiate the different subtypes of non-small cell lung cancer on the molecule response signal under the condition of not knowing tumor markers of the non-small cell lung cancer. Using the aptamer of the invention for identifying the combined target is good for discovering the tumor markers of the different subtypes of non-small cell lung cancer, and earlier and exactly diagnosing and typing non-small cell lung cancer and discovering the tumor for treating new drug action targets.

The invention discloses an electrochemical immunoassay method based on Au-PB-SiO2 composite nano-particles. The detection method adopts a double antibody sandwich method, allows neuron-specific enolase antibodies solid-supported on an electrode surface to perform an immunoreaction with neuron-specific enolase in a sample solution, and to combine with a co-coupled substance of Au-PB-SiO2 composite nano-particles and neuron-specific enolase antibodies. Based on the electrochemical activity of Au-PB-SiO2 composite nano-particles, the detected peak current value of a cyclic voltammetry reduction peak is positively correlated with the concentration of the neuron-specific enolase, and thus the concentration of the neuron-specific enolase in the sample to be detected can be detected. The electrochemical immunoassay method provided by the invention has a corresponding linear range of 0.25-500 ng/ml, and a lower detection limit of 0.08 ng/ml, has good specificity and high sensitivity, and has important significance for the diagnosis of small cell lung cancer (SCLC).

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

The invention discloses an NSCLC (non-small cell lung cancer) detection kit and an application thereof. The NSCLC detection kit comprises substances for detecting the content of 9 miRNAs (miRNA-hsa-miR-20a, hsa-miR-25, hsa-miR-223, hsa-miR-320, hsa-miR-222, hsa-miR-146a, hsa-miR-191, hsa-miR-24 and hsa-miR-130a), CEA and CYFRA21-1. The kit can be used for well screening NSCLC and is high in sensitivity, high in specificity and suitable for screening of NSCLC, particularly for NSCLC at the early stage. Therefore, early warning can be given for the lung cancer risk of people by use of the 9 miRNAs in combination with the CEA and CYFRA21-1, and the early diagnosis proportion can be increased.

The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.

The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.

The invention relates to substituted benzamide compounds shown as a general formula (I) or medicinal salts thereof, preparation of the compounds or the medicinal salts thereof, a medicament composition containing the compounds or the medicinal salts thereof and application of the compounds in treatment of cancers, in particular application in treatment of head and neck cancers, non-small cell lung cancer, pancreatic cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer and flat cell cancer and application in medicaments for treating the cancers.

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

This present invention compositions and methods of treating, diagnosing, prognosing cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.

The invention relates to the field of computers, in particular to a method for analyzing the proportion of PD-L1 positive tumor cells in non-small cell lung cancer and storage equipment. The method for analyzing the proportion of the PD-L1 positive tumor cells in the non-small cell lung cancer comprises the following steps: acquiring a section to be dyed; carrying out immunohistochemical stainingoperation on a tumor cell marker; carrying out immunohistochemical staining operation on a specific marker; obtaining a first region of interest, obtaining feature points, and calculating the total number of tumor cells according to the number of the feature points; obtaining feature points according to a second region of interest, and calculating the number of tumor cells stained by the specificmarker according to the feature points; and calculating the positive proportion fraction of the tumor cells according to the total number of the tumor cells and the number of the tumor cells dyed by the specific marker. In the whole process, a pathologist does not need to perform manual interpretation, so that the obtained result is more accurate and objective, and the efficiency is higher.

The invention relates to a binary classification method for processing non-small cell lung cancer data with missing values and imbalance, and belongs to the technical field of data classification. Themethod comprises the following steps: preprocessing data, filling missing values with medians, eliminating abnormal values by using a Tukey's method, and normalizing the data by using deviation standardization; secondly, carrying out data balance by adopting an SMOTEENN comprehensive sampling method combining oversampling and undersampling; finally, the balanced data set is used for training a random forest classifier, the classification effect is tested on the test set, and therefore the non-small cell lung cancer survival prediction dichotomy method effectively aiming at the problems of missing values and class imbalance is achieved. Experiments performed on a non-small cell lung cancer data set prove the effectiveness and superiority of the method, the classification precision of the non-small cell lung cancer data with missing values and imbalance is improved, and more accurate medical decisions can be achieved.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

The invention belongs to the technical field of immunotherapy prognosis, and in particular relates to a method for immunotherapy prognosis of non-small cell lung cancer (NSCLC) patients. The method uses a gene NFE2L2 and/or KEAP1 as a biomarker, whether the biomarker is mutated or not is detected, and thereby the prognosis of the sensitivity of NSCLC patients to immunotherapy, especially immunotherapy with immune checkpoint inhibitors (ICIs) is performed. In addition, the invention also provides a kit including biomarker detection reagents and an application of the kit. The method or the kit of the invention can be used to accurately predict the population sensitive to ICIs immunotherapy among NSCLC patients with NFE2L2 and/or KEAP1 mutations, and thereby the effectiveness and clinical benefit of immunotherapy for such patients are improved.

The invention discloses application of a serum molecular marker combination as a lung cancer diagnosis and curative effect monitoring marker, belonging to the field of immunodetection. The content of protein (OPN, SAA, CRP, CEA, CYFRA21.1, MIF, AGP, HGF, E-selectin, GRO and NSE) in 11 serums is measured through a Luminex protein chip diagnosis technology. The eight serum protein molecular markers are OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF. The eight serum protein molecular markers have significant promotion effect on a non-small cell lung cancer (NSCLC) and a small cell lung cancer (SCLC). A three-protein detection combination formed by OPN, CEA and another protein (CRP, SAA, CYFRA21.1 or NSE) has excellent diagnosis potential on NSCLC. Compared with the prior art, the serum molecular marker combination has the beneficial effects that the content of multiple protein molecular markers of serum of a patient with lung cancer is detected, and the serum molecular marker combination can be used for lung cancer diagnosis and curative effect monitoring through coordinated comparative analysis of the multiple protein molecular markers.

The invention discloses application of miR-340 as a marker of detecting non-small-cell lung cancer metastasis, or as a marker of pre-judging the risk of non-small-cell lung cancer metastasis, or as a drug resistance marker for non-small-cell lung cancer. It is discovered that the miR-340 can target at downregulation of the expression level of death-associated protein kinase, the death-associated protein kinase being closely related to the metastasis and drug resistance of non-small-cell lung cancer. The increase in expression of the miR-340 indicates the increase in the chances of non-small-cell lung cancer metastasis, causing drug resistance and bad prognosis. On this basis, the moiR-340 can also serve as a target for inhibiting/preventing non-small-cell lung cancer adhesion or attack or inhibiting/preventing non-small-cell lung cancer drug resistance and can also be further popularized and applied to the prevention, treatment and prognosis of other tumor cells. The miR-340 is a new diagnostic tool provided for the clinical molecular-level diagnosis of non-small-cell lung cancer metastasis and drug resistance, and a new drug target is provided for the genetic therapy of non-small-cell lung cancer metastasis.

The invention relates to a diarylpyrimidine compound, a composition and application. The diarylpyrimidine compound is particularly a compound as shown in a general formula (I), and all substituent groups of the general formula (I) are as defined in the description. The invention further relates to application of the compound as shown in the general formula (I) or a pharmaceutically acceptable salt or the pharmaceutical composition in treating tumor diseases, particularly treating a non-small cell lung cancer, a small cell lung cancer, squamous-cell carcinoma, a breast cancer and lymphocytic leukemia by inhibiting epidermal growth factor receptor (EGFR) protein tyrosine kinase (PTK). Please see the formula in the description.

The invention discloses a targeted protein degradation c-Met degradation agent as well as a preparation method and application thereof. The invention provides a c-Met degradation agent based on a targeted protein degradation PROTAC strategy, a preparation method thereof and application of the c-Met degradation agent in the treatment of non-small cell lung cancer, gastric cancer and other cancers.The compound has a remarkable c-Met degradation effect and a remarkable cell proliferation inhibition effect, has the potential of serving as an anti-tumor drug to treat tumors, shows remarkable proliferation inhibition activity in an EBC1 drug-resistant cell strain constructed by lentiviral transfection, is obviously superior to a small molecule inhibitor LXM262. and obviously improves the cell selectivity. The compound has significant advantages in overcoming tumor c-Met acquired drug resistance, especially the compound S27 only provides good activity for c-Met dependent EBC-1 lung cancer cells, it is indicated that the compound S27 has good cell selectivity while the original small molecule inhibitor is multi-target, and the compound also has an inhibition effect on a c-Met non-dependent cell line.

The invention relates to a novel heterocyclic derivative having a formula (I) and salt. The novel heterocyclic derivative comprises pharmaceutical salt, wherein R1, R2, R3, R4, X, Z and L are defined in the text. Compounds of the novel heterocyclic derivative are a CDK (cyclin-dependent kinase) 4/6 inhibitor and an HDAC (histone deacetylase) inhibitor and can be used for treating diseases mediated by CDK4/6 and HDAC and disturbances, such as cancer including mantle cell lymphoma, liposarcomata, non-small cell lung cancer, melanomas, squamous cell esophagus cancer and breast cancer. The invention also relates to a pharmaceutical composition containing the compounds provided by the invention, and also relates to application of the compounds or pharmaceutical composition containing the compounds provided by the invention to treatment of related disturbances. <FORMULA I>.

The invention discloses a novel benzo-heterocyclic bipyrimidine inhibitor having CDK or HDAC inhibitory activity. The inhibitor relates to a novel heterocyclic derivative shown in a formula (I) and asalt thereof, including a medicinal salt, wherein R<1>, R<2>, R<3>, R<4> and R<5> and X, Z and L are defined in the description. The compound is a CDK or HDAC inhibitor, and can be used for treating diseases and disorders mediated by CDK or HDAC, such as cancer, including mantle cell lymphoma, liposarcoma, non-small cell lung cancer, melanoma, squamous cell esophageal cancer, breast cancer, etc. Apharmaceutical composition containing the compound is also related. To treat related disorders by using the compound or the pharmaceutical composition containing the compound is also related. The structure of the novel heterocyclic derivative is shown in the formula (I).

The invention provides a kit for diagnosis of early non-small cell lung cancer. A marker of the kit is protein of serum exosomes, and the exosome protein is exosome human fetuin A, namely AHSG or/andexosome extracellular matrix protein-1, namely ECM-1. The content of the marker in a sample is detected, and if the content of the marker in the sample is greater than the critical value range thereof, a tester can preliminarily judge that the sample has larger risk of non-small cell lung cancer. The marker in the kit is simple to extract, the preparation is convenient and rapid, the detection process is simple, and the kit has a good diagnostic effect on early non-small cell lung cancer.

The invention relates to the effect of miR-451a cells in the non-small cell lung cancer. Migration of A549 cells can be significantly inhibited through overexpression of miR-451a in the A549 cells. By means of the bioinformatics analysis means, it is predicted that translation of the target gene mRNA is inhibited or the target gene mRNA is directly degraded by miR-451a through regional complementation with 3'-UTR of the target gene CAB39 mRNA; it is determined that the CAB39 gene is the target gene of miR-451a through double-luciferase reporter gene system analysis and Western Blot experiment verification. Finally, it is verified through the Transwell Assay and Flow Cytometry Assay experimental means that miR-451a performs the function of inhibiting migration of cells by reducing the CAB39 gene in the A549 cells, and a novel accurate treating researching and treating scheme is provided. By means of the effect, important research guidance and application value is provided for using miRNA for diagnosing and treating the non-small cell lung cancer and searching for drug targets in the fields such as tumor immunotherapy clinically.